Quintrio
Home

SERVICES-MEDICAL LABORATORIES

Advanced Biomed Inc. Common Stock

ADVB

Advanced Biomed Inc operates through its subsidiary as an AI financial verification company focused on financial verification and other professional, regulated use cases. The Group develops and operates the FinTruth Financial Verification Agent Platform (FinTruth), an enterprise AI financial verification platform designed to compare and verify financial analysis and AI-generated financial content against underlying source documents and financial rules, and to produce source-traceable and auditable results. It focuses on establishing recurring and usage-based enterprise revenue from its AI technology operations. The Group has one reportable segment, consisting mainly of its technology and software-related operations.

Last trade $2.15
Day change -$0.07 (-3.15%)
Day range $2.10 – $2.30
Volume 20,600
Market cap $4M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$3.67M
Price / earnings
0.6×
Price / book
0.32×
Price / sales
28.74×
EV / sales
27.06×
EV / EBITDA
-0.5×

Profitability

Earnings per share
$3.68
Return on assets
47.08%
Return on equity
53.82%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
8.09×
Quick ratio
8.09×
Cash ratio
0.13×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$1.51M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for ADVB, quarterly periods
Line itemQ1 FY2027 Sep 30, 2026Q4 FY2026 Jun 30, 2026Q3 FY2026 Mar 31, 2026Q2 FY2026 Dec 31, 2025Q1 FY2026 Sep 30, 2025Q4 FY2025 Jun 30, 2025Q3 FY2025 Mar 31, 2025
Revenue$0$127.64K$0$0$0$0$0
Cost of revenue$0$0$0$0$0$0$0
Gross profit$0$127.64K$0$0$0$0$0
Selling, general and administrative$973.93K$5.71M$276.61K$210.31K$147.16K$611.38K$347.54K
Research and development$0-$665.14K$243.23K$186.33K$0-$600.06K$219.97K
Total operating expenses$973.93K$5.05M$519.84K$396.64K$147.16K$11.32K$567.51K
Operating income-$973.93K-$4.92M-$519.84K-$396.64K-$147.16K-$11.32K-$567.51K
Interest expense-$15.12K-$7.01K$0$0$0$0$0
Income before taxes-$989.05K-$12.52M-$488.94K$7M-$147.16K$675.64K-$1.2M
Income taxes$0-$1.21K$0$0$0$0$0
Net income-$989.05K$695K-$488.94K$6.86M-$386.9K-$701.61K-$1.38M
Net income attributable to common shareholders-$989.05K$695K-$488.94K$6.86M-$386.9K-$701.61K-$1.38M
EBITDA-$973.93K-$4.97M-$510.51K-$409.5K-$147.16K-$79.29K-$545K
Basic earnings per share-$0.60$0.44-$0.38$6.20-$0.36-$0.65-$1.35
Diluted earnings per share-$0.60$0.44-$0.38$6.20-$0.36-$0.65-$1.35

Recent news

Company coverage with links to the original publishers.

Publication times in UTC

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Feb 20, 20261-for-20reverse split